Chlorogenic Acid in Antitumor Therapy: Multi-Pathway Mechanisms, Nanocarrier-Mediated Smart Delivery, and Synergistic Combinatorial Strategies Authors: Huijuan Duan, Juan He, Rui Wang, Jie Wu, Haitao Ding Published: 2026 ABSTRACT AbstractMalignant tumors remain a global public health challenge with high morbidity and mortality. Conventional therapies are limited by severe adverse effects and drug resistance. Chlorogenic acid (CGA), a widely distributed phenolic compound, has emerged as a promising antitumor agent due to its excellent biocompatibility and multi-targeted bioactivities, including antioxidant, anti-inflammatory, immunomodulatory, and pro-apoptotic. This review systematically summarizes the molecular mechanisms underlying the antitumor activity of CGA, focusing on three core aspects: (1) regulation of key signaling pathways (Janus kinase-signal transducer and activator of transcription (JAK-STAT), Mitogen-Activated Protein Kinase (MAPK), Nuclear factor kappa-B (NF-κB)) in tumor cells; (2) enhancement of host antitumor immune function through immune‑cell activation and cytokine‑network modulation; and (3) induction of tumor cell apoptosis via B-cell lymphoma 2 (Bcl-2) family regulation, oxidative stress, and metabolite synergy. Furthermore, we highlight recent advances in nanocarrier-facilitated delivery of CGA, including metal-based nanocomposites, metal oxide nanoparticles, and functionalized liposomes, and establish a horizontal comparison table to analyze their respective delivery efficiency, tumor accumulation, biosafety and immune activation capacity, which effectively overcome its pharmacokinetic shortcomings, such as short circulation half‑life and poor tumor accumulation. Additionally, synergistic antitumor effects achieved by combining CGA with chemotherapy drugs or immune checkpoint inhibitors across melanoma, lung cancer, colon cancer and hepatocellular carcinoma models are comprehensively discussed. This review provides a comprehensive theoretical foundation for the further development of CGA as a promising antitumor agent and its clinical translation, and outlining operable key challenges and future research directions.Keywords: signaling pathway, immunomodulation, apoptosis, nanodelivery, synergistic therapy, biocompatibility Introduction Malignant tumors rank among the most lethal diseases worldwide, posing a formidable threat to public health and lifespan. The International Agency for Research on Cancer projects approximately 21.4 million new cancer cases and 13.2 million cancer-related deaths will occur annually by 2030.1 Conventional therapeutic modalities, including surgical resection, chemotherapy and radiotherapy, are largely restricted by intrinsic drawbacks such as severe off-target systemic toxicity, nonselective tumor cell ablation, and inevitable multidrug resistance, which severely restrict their clinical therapeutic outcomes.2 Consequently, developing high-effective low toxicity antitumor drugs has become an urgent and persistent research priority. Natural products have garnered considerable attention in this field owing to their structural diversity, broad biological activities, and favorable toxicity profiles. Chlorogenic acid (CGA, also abbreviated as CHA or CA), a ubiquitous phenolic metabolite in plants (Figure 1),3 is biosynthesized via esterification between caffeic acid and quinic acid.4 Its molecular structure encompasses labile moieties, including ester bonds and unsaturated double bonds, and it is predominantly found in coffee and tea. CGA exhibits excellent biological safety: in the body, intact CGA is partially absorbed in the stomach, while the majority undergoes intestinal hydrolysis catalyzed by small and large intestinal esterases to generate caffeic acid and quinic acid prior to systemic uptake.5,6 Multiple toxicological studies have validated its low systemic toxicity: continuous oral intake of green coffee bean extract rich in CGA (1 g/kg) for two consecutive weeks induced no observable adverse physiological responses in mice;7 a single oral dose of 2 g/kg green coffee bean extract containing 50% CGA caused no toxic manifestations in rats; furthermore, daily administration of CGA at 250, 500 and 1000 mg/kg over three months triggered no detectable organ damage or physiological abnormalities in experimental animals.8 Additionally, CGA possesses various biological activities, including antioxidant, antibacterial, anti-inflammatory, antitumor, and immunomodulatory effects.9–11 Preclinical investigations have verified its therapeutic potential against a broad spectrum of malignancies, including breast cancer,12 brain tumors,13 lung cancer,14 colon cancer15 and chronic myeloid leukemia.16 Structure of CGA.3 Copyright (2024) MDPI. Despite prominent antitumor potency validated in cell and animal models, the clinical transformation of CGA is severely hindered by multiple interconnected pharmacological bottlenecks. To date, clinical investigations involving CGA remain at an exploratory stage, with the majority of registered trials confined to evaluating its safety profile and preliminary therapeutic efficacy as a dietary supplement or adjunct to conventional regimens. Notably, no CGA monotherapy has yet progressed to late-phase clinical trials for oncological indications. Three core barriers impede its clinical development: (i) Suboptimal pharmacokinetic properties: CGA displays an exceptionally short plasma half-life (approximately on the order of minutes) and rapid systemic clearance, failing to sustain therapeutically effective concentrations within tumor parenchyma;17,18 (ii) Limited oral bioavailability: Following gastrointestinal administration, extensive presystemic metabolism mediated by gut microbiota and intestinal esterases degrades most intact CGA molecules, drastically reducing the fraction of bioactive agents reaching systemic circulation and tumor lesions;19,20 (iii) Lack of intrinsic tumor tropism: CGA bears no specific binding affinity for malignant tissues, leading to ubiquitous biodistribution across healthy organs and compromised overall therapeutic efficacy. Collectively, these pharmacokinetic and biopharmaceutical deficits create a striking paradox: robust in vitro antitumor activity contrasts sharply with unsatisfactory in vivo therapeutic performance, highlighting an urgent demand for innovative delivery platforms and rationally designed combination regimens to facilitate the clinical translation of CGA. Against this background, nanocarrier-based delivery systems and combinatorial therapeutic strategies have emerged as effective solutions to break through the above limitations and improve the translational efficiency of CGA. This review comprehensively dissects the multi-pathway antitumor mechanisms of CGA, with a focus on signal pathway regulation, immune function enhancement, and tumor cell apoptosis induction. Furthermore, we systematically summarize the latest advances in nanocarrier-mediated CGA delivery (metal-based nanocomposites, metal oxides, functionalized liposomes) and their synergistic effects with chemotherapy or immunotherapy. This work aims to provide a novel theoretical framework for overcoming CGA’s translational barriers and guiding its clinical application in precision antitumor therapy. Antitumor Mechanisms of CGA Tumor initiation and progression represent intricate pathological cascades driven by dysregulated cell proliferation, impaired apoptotic signaling, immune evasion and aberrant oncogenic signaling networks. CGA executes multifaceted antitumor effects by targeting multiple molecular nodes and biological pathways, with three core mechanistic branches summarized below (Figure 2). The antitumor mechanism of CGA. Abbreviations: TLR, Toll-like receptor; TNF-α, tumor necrosis factor-α; IL, interleukin; MCP-1, monocyte chemoattractant protein‑1; MIP-1α, macrophage inflammatory protein‑1α; JAK, Janus kinase; STAT, signal transducer and activator of transcription; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; JNK, Jun N-terminal kinase; NF-κB, Nuclear factor kappa-B; IκBα, inhibitor of the nuclear factor kappa B; Bax, Bcl-2-associated X; Bcl-2, B-cell lymphoma 2; mtDNA, mitochondrial DNA; nucDNA, nuclear DNA. Bold text represents CGA exerts antitumor effects via three core mechanisms, including tumor-associated signaling pathway, host immune function and apoptosis. Black arrows indicate the increase or decrease expression. Arrows represent activation, T-bars represent inhibition. Regulation of Tumor-Associated Signaling Pathways The aberrant activation of cell signal pathways serves as a critical molecular driver underlying the malignant proliferation, invasion and metastasis of tumor cells. CGA interferes with the biological behaviors of tumor cells by targeting and regulating multiple signaling pathways. JAK-STAT Signaling Pathway Modulation of the tumor microenvironment (TME) and key JAK-STAT signaling cascades occupies a central position in CGA-mediated antitumor immunity (Figure 3).21 Macrophages polarization status directly affects tumor progression: M1-type tumor-associated macrophages (TAMs) exhibit clear antitumor activity, whereas M2-type TAMs promote tumor proliferation, angiogenesis, migration and invasion. Notably, signal transducer and activator of transcription 1 (STAT1) and signal transducer and activator of transcription 6 (STAT6) are the key molecules regulating the polarization of M1 and M2-type macrophages.22,23 Schematic representation of the inhibitory effects of CGA on intestinal diseases signaling pathways.21 Copyright (2025) Royal Society of Chemistry. Abbreviations: MyD88, myeloid differentiation primary response gene 88; NLRP3, nucleotide-binding domain-like receptor protein 3; ASC, apoptosis-associated speck-like protein containing a caspase-activation and recruitment domain; CASP1, caspase-1. Cumulative evidence demonstrates that CGA functions as a potent immunomodulatory antitumor agent: it promotes STAT1 phosphorylation, suppresses STAT6 activation, modulates Lipopolysaccharide (LPS)/Interferon-gamma (IFN-γ) and IL-4 responsive transcriptional programs, and drives phenotypic repolarization of TAMs from protumor M2 to antitumor M1 subsets,23 which collectively remodels an immunostimulatory TME and suppresses glioblastoma progression.24 In melanoma models, Li et al25,26 demonstrated that CGA treatment significantly decreased the proportion and functional activity of M2-like TAMs and CD4⁺Foxp3⁺ regulatory T cells (Tregs) in mice, whereas the proportion and functional activity of CD8⁺ T cells and M1-like TAMs were markedly elevated. This regulatory effect was closely associated with the JAK-pSTAT1-IRF1 signaling pathway. Furthermore, CGA inhibits the progression of osteosarcoma cells and induce tumor cell apoptosis by reducing STAT3 phosphorylation and the expression of STAT3 and Snail proteins, thereby blocking the STAT3/Snail pathway.27 Collectively, the JAK-STAT pathway serves as a critical target for CGA to exert its antitumor effects. MAPK Signaling Pathway The MAPK cascade represents another critical regulatory target for CGA to exert its antitumor effects. As a core intracellular signal transduction network, the MAPK pathway governs fundamental biological events including cell proliferation, differentiation, apoptosis and stress responses, comprising three core branches: extracellular signal-regulated kinase (ERK), Jun N-terminal kinase (JNK), and p38 MAPK.28 This pathway can be activated by various stress stimuli such as growth factors, inflammatory cytokines, and oxidative stress and transmits extracellular signals to the nucleus via a phosphorylation cascade, thereby regulating the expression of target genes to mediate cellular biological effects.29 Previous studies have confirmed that CGA can exert antitumor effects by inhibiting the aberrant activation of the MAPK pathway in tumor cells. At the level of inflammation regulation, CGA targets and inhibits the activation of the JNK/activating protein-1 pathway, reduce the transcription and expression of cyclooxygenase-2 (COX-2), and thereby decrease the synthesis of prostaglandin E2, ultimately abrogating the promotional effect of the inflammatory microenvironment on tumor progression.30 For cell proliferation and apoptosis regulation, CGA significantly inhibit the phosphorylation activity of ERK, reduces tumor cell viability, and induces apoptosis.31,32 Notably, the aberrant activation of ERK has been identified as a key driver of cancer metastasis in multiple tumor types.33 More importantly, when CGA is combined with nanomaterials or chemotherapy drugs, its regulatory effects on the MAPK pathway are further potentiated, providing a novel strategy for its antitumor application. With regard to nanocarrier-facilitated delivery, CGA-selenium nanoparticles (CHSe NPs) can specifically modulate the expression of Mapk8ip1, a key upstream regulatory protein in the MAPK pathway, thereby breaking the “oxidative stress-inflammation” vicious cycle. In the acute lung injury model, CHSe NPs exhibit superior anti-inflammatory efficacy compared to dexamethasone,34 offering new insights for subsequent research on TME regulation. In a colon cancer model, CGA downregulates the expression of p-ERK and p-JNK proteins, alleviating colonic tissue damage and inflammatory responses, further verifying its targeted regulatory effect on the MAPK pathway (Figure 3).21,35 Moreover, although the multi-kinase inhibitor regorafenib exerts a distinct inhibitory effect on the MAPK cascade, its impact on the PI3K/AKT signaling pathway is relatively limited.36 In contrast, the combination of CGA and regorafenib synergistically enhances the dual inhibition of the MAPK pathway and the PI3K/Akt/mammalian target of Rapamycin (mTOR) pathway, markedly suppressing hepatocellular carcinoma cell proliferation and inducing apoptosis,37 demonstrating a “1 + 1 > 2” synergistic antitumor effect. NF-κB Signaling Pathway The NF-κB pathway is another critical target for CGA in regulating tumor occurrence and development. As a ubiquitously expressed transcription factor, NF-κB plays a core regulatory role in inflammatory response, immune regulation, cell proliferation, apoptosis, and angiogenesis within the TME. Under normal physiological conditions, NF-κB forms an inactive complex with inhibitor of NF-κB (IκB) family proteins (eg, Inhibitor of the nuclear factor kappa B (IκBα)) in the cytoplasm. Upon stimulation by LPS, pro-inflammatory factors and other external stimuli, the IκB kinase (IKK) complex is activated, triggering the ubiquitination and degradation of IκBα and releasing free NF-κB dimers (eg, p65/p50). These dimers then translocate into the nucleus, bind to κB response elements within target promoter genes, and initiate the transcription of downstream pro-inflammatory cytokines and anti-apoptotic genes, ultimately facilitating tumor progression.38 Recent evidence has confirmed that CGA exert antitumor and anti-inflammatory protective effects by targeting the abnormal activation of the NF-κB pathway. In the RAW264.7 macrophage model, CGA downregulated the phosphorylation of IKK, reduced the degradation of IκBα, and significantly inhibited LPS‑induced nuclear translocation of the NF‑κB p65 subunit, thereby blocking the activation of the NF‑κB signaling pathway. This ultimately led to a decrease in the release of pro‑inflammatory cytokines, such as tumor necrosis factor α (TNF-α) and Interleukin 6 (IL‑6), and attenuating cellular inflammatory responses.30 In chemotherapy-induced intestinal mucositis models, CGA directly reduces phosphorylation and nuclear translocation of NF-κB p65, suppressing NF-κB-dependent transcription of proinflammatory factors such as IL-1β and COX-2, alleviating inflammatory mucosal damage and preserving intestinal barrier integrity.39,40 Notably, by virtue of its antioxidant capacity, CGA alleviates chemotherapy-induced adverse effects through multi-pathway synergistic mechanisms: (1) it suppresses Toll-like receptor 4 (TLR4) activation, blocks the TLR4/NF-κB/MAPK cascade, and diminishes the production of oxidative stress-related mediators (eg, reactive oxygen species (ROS), malondialdehyde); (2) it activates the 5′-adenosine-monophosphate-activated protein kinase (AMPK)/silent information regulator 1 (SIRT1) pathway, upregulates the activity of antioxidant enzymes (eg, superoxide dismutase (SOD), glutathione peroxidase), and attenuates the aberrant activation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway to mitigate apoptosis (Figure 4).41 These multi‑target regulatory effects enable CGA to effectively alleviate 5‑fluorouracil (5‑FU)‑induced intestinal mucosal injury, providing a novel research direction for its clinical application in mitigating chemotherapy‑related side effects in cancer treatment. A scheme displaying the protective effect of CGA against 5-FU-induced mucositis.41 Copyright (2025) Elsevier. Abbreviations: HO-1, heme oxygenase 1; GPx3, glutathione peroxidases 3; Nrf2, nuclear-factor-erythroid-2-related factor 2; iNOS, inducible nitric oxide synthase. Crosstalk Between Signaling Pathways The three pathways regulated by CGA exhibit extensive bidirectional upstream-downstream crosstalk. Herein, we systematically summarize their feedback regulatory loops modulated by CGA, which will be visualized in a supplementary pathway interaction network diagram: (1) NF-κB to JAK-STAT axis: Activated NF-κB transcriptionally upregulates suppressor of cytokine signaling 3 (SOCS3), a classic endogenous inhibitor of JAK-STAT, which suppresses STAT1/STAT6 phosphorylation to limit anti-tumor macrophage polarization. CGA interrupts this feedback loop by stabilizing IκBα to block NF-κB nuclear entry, relieving SOCS3-mediated STAT1 inhibition and amplifying M1 polarization.21,41 (2) JAK-STAT to NF-κB axis: CGA-induced STAT1 activation promotes IκBα protein synthesis and stability, directly restraining p65 nuclear translocation and downstream pro-inflammatory cytokine secretion, forming a negative feedback to suppress NF-κB hyperactivation.21,41 (3) MAPK-NF-κB mutual regulation: JNK/ERK phosphorylation serves as upstream activators of IKK complex to accelerate IκBα degradation. CGA simultaneously inhibits ERK/JNK phosphorylation and NF-κB p65 nuclear translocation; dual pathway suppression synergistically reduces COX-2 expression and prostaglandin E2 accumulation, alleviating chronic inflammatory TME.30 In summary, CGA synchronously intervenes three axes to form a multi-layered inhibitory network, simultaneously inhibiting tumor cell proliferation, reducing inflammatory factor secretion and reshaping TAM polarization, which significantly improves the specificity and potency of anti-tumor effects (Figure 5). Schematic diagram of the crosstalk network among JAK-STAT, MAPK and NF-κB signaling pathways regulated by CGA in tumor cells. Enhancement of Host Immune Function The antitumor surveillance function of the immune system is the core defense line for the host to eliminate abnormal tumor cells. CGA can enhance the host’s antitumor immune response by activating the activity of immune cells, regulating the immune factor network, and reshaping the tumor immune microenvironment, providing important immune support for tumor therapy. Activation of Core Immune Cells CGA can specifically activate the functions of key antitumor immune cells, including natural killer (NK) cells, T lymphocytes (CD4⁺ helper T cells, CD8⁺ cytotoxic T cells), and macrophages, achieving precise regulation of the immune response by modulating relevant signaling pathways. Studies have shown that CGA can activate the functions of immune cells, inhibit the overexpression of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, and induce the generation of Tregs, maintaining host immune homeostasis of the body.42,43 In the tumor immune microenvironment, CGA induces the M2-to-M1 polarization of TAMs, directly suppressing the proliferation of B16F10 melanoma cells. Notably, when combined with anti-programmed cell death protein 1 (anti-PD-1) antibodies, CGA synergistically reduces the proportion of CD4⁺Foxp3⁺ Tregs and elevates the proportion of CD8⁺ T cells, markedly boosting the host’s specific antitumor immune response.44 Modulation of Cytokine Networks and Inflammatory Balance CGA precisely modulates the synthesis and secretion of immune cytokines to rectify immune dysregulation, thereby creating a favorable microenvironment for antitumor immunity. On the one hand, CGA can inhibit the excessive production of pro‑inflammatory cytokines, including TNF‑α, IL‑1β, IL‑6, monocyte chemoattractant protein-1 (MCP‑1), and macrophage inflammatory protein‑1α (MIP‑1α),45,46 thereby blocking the promotion of tumor progression by the chronic inflammatory microenvironment. On the other hand, CGA can downregulate the abnormal activation of TLRs. By balancing cytokine and chemokine release, CGA alleviates pathology induced by sepsis, reflecting its broad‑spectrum immunomodulatory properties.47–49 In IL‑10 knockout mice—a classic inflammatory bowel disease model—CGA administration significantly improved immune‑related disorder markers, including intestinal inflammatory infiltration, elevated expression of inflammatory proteins, and T‑cell imbalance.50 This further confirms CGA’s ability to regulate abnormal immune states and its synergistic role in anti‑inflammatory and immune‑modulatory processes. Induction of Tumor Cell Apoptosis Inducing tumor cell apoptosis is a core mechanism of CGA’s antitumor action. A prominent pharmacological characteristic of CGA lies in its excellent tumor-selective cytotoxicity: it effectively suppresses proliferation and triggers apoptosis in various malignant tumor cells, while exerting negligible cytotoxicity and even significant protective antioxidant effects on normal somatic cells. Notably, this dual differential effect is primarily attributed to the inherent differences in oxidative stress homeostasis, metabolic patterns, TME properties, and potential membrane transporter expression between normal cells and tumor cells, which endow CGA with precise tumor-targeting pro-apoptotic activity. First, normal cells and tumor cells exhibit distinct basal redox and metabolic profiles, laying the fundamental basis for CGA’s selective action. Normal somatic cells maintain stable intracellular redox homeostasis with abundant endogenous antioxidant reserves, including SOD, glutathione peroxidase (GSH-Px), catalase (CAT), and sufficient reduced glutathione (GSH).38,51 Under physiological conditions, CGA acts as a potent antioxidant in normal cells by scavenging excess ROS, activating the nuclear factor erythroid-2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) antioxidant signaling pathway, and upregulating the expression and activity of antioxidant enzymes, thereby eliminating mild oxidative stress and protecting cell viability.38 Consistent with this protective effect, multiple studies have verified that CGA alleviates oxidative damage, delays endothelial senescence, and improves cellular antioxidant capacity in normal cells.52 For instance, CGA treatment significantly reduces aluminum-induced increases in intracellular malondialdehyde (MDA) levels and restores the activities of SOD, CAT, and GSH, effectively ameliorating aluminum-triggered immunotoxicity.53 Moreover, CGA exerts prominent hepatorenal protective effects via regulating oxidative stress-related proteins, balancing programmed cell death, and inhibiting inflammatory responses in normal hepatic and renal tissues. The stable metabolic phenotype and intact antioxidant defense system of normal cells enable them to tolerate CGA intervention, avoiding the initiation of cell death programs.38 In contrast, tumor cells possess unique metabolic maladaptations and redox imbalance that render them highly susceptible to CGA-induced lethal oxidative damage. Malignant tumor cells rely on aerobic glycolysis to support rapid proliferation, which intrinsically elevates basal intracellular ROS levels and continuously consumes endogenous GSH antioxidant reserves, resulting in a chronically high oxidative stress state and a fragile redox balance. Unlike normal cells with robust antioxidant defense, tumor cells lack sufficient residual antioxidant capacity to counteract exogenous oxidative perturbations. CGA further disrupts mitochondrial electron transport chain function, exacerbates intracellular lipid peroxidation, and depletes the remaining GSH pools in tumor cells. This comprehensive oxidative damage pushes tumor cells beyond the lethal oxidative threshold, ultimately triggering multiple cell death modalities including mitochondrial-mediated apoptosis, ferroptosis, and cuproptosis. Second, the unique physicochemical properties of the TME further amplify CGA’s selective pro-apoptotic efficacy in tumor tissues, while the physiological microenvironment of normal tissues eliminates CGA’s cytotoxic activity. The TME is characterized by acidic extracellular pH, hypoxia, high GSH concentration, and excessive inflammatory cytokine infiltration. The acidic TME induces conformational transformation of the polyhydroxyl structure of CGA, which significantly enhances the binding affinity of CGA with pro-apoptotic target proteins (Bcl-2-associated X (Bax), p53). Meanwhile, TME hypoxia upregulates HIF-1α expression, which synergizes with CGA to block glycolytic energy metabolism and deprive tumor cells of energy supply, further accelerating tumor cell apoptosis.54,55 Conversely, normal tissues maintain a neutral physiological pH, normoxic conditions, and low basal inflammation. Such a stable microenvironment locks CGA in an inert antioxidant conformation, which only activates antioxidant protective pathways rather than pro-apoptotic signaling cascades in normal cells. Consistent with the above selective mechanisms, multiple in vitro toxicological assays have fully validated the biosafety and tumor-targeting specificity of CGA. CGA treatment causes no obvious viability loss or apoptotic damage in normal hepatocytes, lung epithelial cells, and lymphocytes, whereas it inhibits the proliferation of homologous tumor cell lines in a dose-dependent manner. Mechanistically, CGA triggers tumor cell apoptosis through multiple targeted pathways. It precisely remodels the homeostasis of Bcl-2 family gene expression in tumor cells: it markedly downregulates the transcription levels of anti-apoptotic genes (Bcl-2, Bcl-XL) to weaken tumor cell anti-apoptotic ability, and simultaneously upregulates the expression of pro-apoptotic genes (Bax, Bcl-XS, Bad) to amplify apoptotic signal transduction.37,56 Moreover, CGA significantly upregulates p53 gene expression in tumor cells and activates p53-mediated downstream apoptotic signaling pathways, with more potent pro-apoptotic effects observed in p53-functional tumor cells.54 Notably, oxidative stress serves as a critical synergistic regulator of CGA’s anti-tumor efficacy. Combined magnetic‑field intervention can further suppress the antioxidant enzyme activity (SOD, GSH-Px, CAT) of CGA-pretreated melanoma cells, further disrupting tumor cell redox balance and strengthening pro-apoptotic effects.57 In addition, CGA metabolites, including caffeic acid, 3-phenylpropionic acid (3-PPA), and benzoic acid, also exert potent tumor apoptosis-inducing activity. Among them, 3-PPA impairs mitochondrial structural and functional integrity by reducing the mitochondrial DNA (mtDNA)/ nuclear DNA (nucDNA) ratio in tumor cells, thereby efficiently inducing tumor cell apoptosis.58 Collectively, these findings demonstrate that CGA exhibits superior tumor-targeting specificity based on cellular metabolic differences, redox heterogeneity, TME characteristics, and potential transporter expression disparities, achieving selective killing of tumor cells while protecting normal somatic cells. Nanocarrier-Mediated Delivery and Clinical Translation of CGA As a small molecule compound, CGA has pharmacokinetic defects such as rapid clearance post-intravenous injection, short blood circulation half-life, and low tumor tissue accumulation rate,59,60 which severely limit its clinical antitumor efficacy. The emergence of nanocarrier technology provides a transformative strategy to surmount these bottlenecks: covalent or noncovalent integration of CGA with functional nanomaterials drastically elevates systemic bioavailability, enhances tumor-targeting tropism and mitigates off-target systemic toxic side effects. Table 1 summarizes representative CGA nanomedicine platforms, their antitumor efficacy and underlying molecular mechanisms. We further systematically compare the merits and drawbacks of diverse nanocarrier architectures with respect to drug delivery efficiency, tumor enrichment capacity, in vivo biosafety and immune activation potency (Table 2). Table 1The Antitumor Effect of CGA and Mechanisms of ActionCancer TypeCompositionsCell LinesLiving ModelInterventional CGA DoseMechanism of ActionRef.Breast cancerAlbumin, CGAMDA-MB-435s C-0.5 μM (IC50)via p53-dependent and PI3/AKT/mTOR inhibition in MDA-MB-435s cells.[61]SnO2, SA, CGAMDA-MB-231-15 μg/mL (IC50)Increased the oxidative stress markers (CAT, SOD and GSH) and MDA levels, thereby facilitating the oxidative stress.[62]PKCMDA-MB-231, MCF-7-75 and 150 μg/mL (24 h)Increased apoptosis, enhanced DNA damage, reduced matrix metalloproteinase (MMP) expression, and activation of the protein kinase C (PKC) signaling pathway.[63]CGA4T14T1 cells (1×10[6] cells per female BALB/c mice).0.6–7.5 mg/mL (24 and 72 h)Inhibited cell viability, migration, and proliferation, along with increased apoptosis.[54]CGAMDA-MB-231, MDA-MB-453, MCF-10A and 4T14T1 cells (1×10[6] cells per mouse)5, 10 and 20 μMBy impairing the NF-κB/EMT pathway, CGA significantly slowed tumor growth, prolonged survival, inhibited pulmonary metastasis, and boosted antitumor immunity by enhancing splenic CD4+ and CD8+ T cell proportions.[64]Topotecan, CGA, peptide sequence (AVNTANSTGSLVHC)EpH4, 1424.1-10 mMDelivered the drug to cancer cells, inducing marked morphological changes and inhibiting proliferation.[65]Colorectal cancerCu[2+], CGACT26Injecting CT26 cells into the right dorsal side of Balb/c mice.300 μg/mLvia ROS production and GSH depletion, inducing pyroptosis, enhances tumor cell sensitivity to cuproptosis; evokes immunogenic death (ICD), releases damage-associated molecular patterns (DAMPs), and promotes dendritic cell maturation and CD8⁺ T cell activation.[66]Immune-elicitable polyphenols, Mitoxantrone (MIT), Fe3+, CGACT26Then CT26 cells (5 × 10[5] cells per female Balb/c nude mice).0.0108 mMAttenuated GPX4-mediated lipid peroxidation inhibition via activating tumoricidal immunity, synergistically enhancing cancer cell ferroptosis.[67]CGACaco-2-50–1000 μMDecreased cell proliferation, induced cell-cycle arrest.[58]HCT116, HT29-125, 250, 500, or 1000μmol/L for 72 hInduced S-phase arrest and ERK inactivation.[68]CGA7HCT116-0.84 mg/mL (IC50).DNA fragmentation, PARP-1 cleavage, caspase-9 activation, downregulation of anti-apoptotic Bcl-2, and upregulation of pro-apoptotic BAX.[69]Au, miRNA-31, CGACRL2577-1000 μMmiR-31 inhibition.[70]CGA, HRPCaco-2, RAW264.7By providing 3.5% DSS (sulfate sodium salt) in drinking water for 7 d.400 μg/mLReduced oxidative stress and levels of inflammatory factors.[71]PET, Fe3O4, OA, CGAHCT 116-30 μg/mLApoptosis-inducing ability against cancer cells.[72]CGAHT29-50 µg/mL (IC50)Via apoptosis induction and excessive ROS-mediated viability reduction.[73]Malignant melanomaDOX, SA-ODAB16F10, RAW264.7By injecting B16F10 cells in male C57BL/6 mice.5 μMBy promoting M2-to-M1 (tumor-promoting to antitumor) transition and direct tumor cell killing.[44]PD-L1, SAL, CGAB16F10, RAW264.7B16F10 cells (1 X 10[6] /mL per C57BL/6 mice.50 μg/mLDecreased M2-TAMs and CD4⁺Foxp3⁺ T cell proportions, with increased M1-TAMs, CD8⁺ T cell proportions, T cell activity, and tumor inhibition rate.[26]Lung cancerCGAA549-50 μMRegulated the expression of apoptosis-related genes and self-renewal-related stem cell markers in cancer cells.[74]Liver cancerGreen-synthesized Pluronic F127, CGAHepG2Male and female zebrafish of similar weights.2-256 μg/mLCytotoxicity, apoptosis induction, and increased ROS production; and activated the apoptotic cascade and regulated PI3K/AKT/mTOR pathways.[75]Graphene oxide, protocatechuic acid, CGAHepG2-100 μg/mLMitochondrial membrane potential depolarization and reactive oxygen species upregulation.[76]LymphomaAg, BSA, CGADLA cellsThe DLA cells (2 × 10[6] cells per female Swiss albino mice).165.53 μg/mLTriggers cytotoxicity, oxidative stress, and chromatin condensation in DLA cells and in vivo anticancer efficacy that enhances the host antioxidant status.[77] The Antitumor Effect of CGA and Mechanisms of Action Table 2Horizontal Comparison of Different CGA-Loaded NanoplatformsNanocarrier TypeTumor Targeting CapacityIn vivo Systemic ToxicityImmune Activation EffectSuitable Tumor ScenariosCore LimitationsRefIron-based nanocompositesHypoxia/TME responsive targetingLow, partial long-term iron accumulation riskStrong ferroptosis + ICD dual activationColorectal cancer, solid tumors with hypoxiaComplex synthesis, unclear long-term biosafety[67,78]Copper-bridged nanoparticlesTumor GSH responsive releaseNegligible at therapeutic doseObvious ICD, DC maturation and CD8+ T activationTumors sensitive to cuproptosis (eg, breast cancer, lung cancer, colorectal cancer)Copper ion overload risk with high dosage[66]Silver nanocompositesPassive targeting via EPR effect; BSA improves bioavailabilityExtremely low, no cytotoxicity to normal mouse lymphocytes; protects normal cellsPrimarily acts via oxidative stress regulation; no direct immune activationOxidative stress‑related tumors (eg, lymphoma)Lack of active targeting capability; distribution in deep tumor tissues may be insufficient[77]Gold nanocompositesPassive targeting via EPR effectLow, green synthesis enhances biocompatibilityExerts anti-inflammatory effects via NF‑κB inhibition, limited immune activationTumors driven by chronic inflammation (eg, colitis-associated colon cancer)Need to balance anti‑inflammatory and antitumor effects; risk of excessive immune suppression[79]SeleniumPassive targeting via EPR effectVery low, synergistic anti-inflammatory and antioxidant effects, alleviates treatment‑related side effectsPromotes M2‑type macrophage polarization, modulates inflammatory TMESolid tumors requiring reduction of radiotherapy/chemotherapy‑induced inflammation (eg, lung cancer)The effect of promoting M2 macrophage polarization may conflict with the need for M1‑type antitumor immunity; requires precise dosing control[34]Metal oxide nanoparticles (SnO2/Fe3O4)Magnetic responsive localizationLow, good biocompatibilityWeak direct immune activation, rely on CGATriple-negative breast cancer, magnetic resonance imaging combined therapyLack of active targeting capability; large‑scale production challenges[62,80]Functionalized liposomesMannose/sialic acid active targeting to TAMsVery low, high biocompatibilitySpecific TAM M2-M1 polarization regulationGlioblastoma, melanomaPoor CGA lipophilicity, complicated preparation[10] Horizontal Comparison of Different CGA-Loaded Nanoplatforms Metal-Based Nanocomposites The development of nanobiotechnology provides technical support for the large-scale application of metal nanoparticles in the field of biomedicine. These particles possess dual attributes of “carrier delivery” and “functional therapy”: Silver, gold, selenium and other nanoparticles can eliminate free radicals through redox activity and exert antioxidant effects;81–83 while metal-based nanoparticles such as manganese,84,85 cobalt,86–88 zinc,89–92 and copper66 can deliver exogenous ions and enhance the sensitivity of tumor cells to ferroptosis/cryptophagy by inducing the generation of ROS, damaging DNA or activating pro-apoptotic proteins. Incorporation of CGA further amplifies these therapeutic outputs while resolving the low delivery efficiency of standalone metallic nanoparticles. Ferroptosis-Targeted Metal Complexes Ferroptosis is a type of cell death driven by iron-dependent lipid peroxidation. Due to abnormal iron metabolism in tumor cells, it has become a specific target for antitumor therapy. Metal-based nanoparticles can potentiate the ferroptotic effect by delivering exogenous Fe3⁺, while synergistic CGA co-loading drastically improves the tumor-targeting specificity and therapeutic efficiency of this process. Chen et al67 designed an oxygen-responsive CGA-iron-based nano-inducer: the nanocore self-assembles from immune-stimulatory polyphenols, CGA, and the chemotherapeutic agent mitoxantrone, followed by Fe3⁺ chelation and encapsulation within a hypoxia-responsive hybrid lipid bilayer. This system demonstrated precise targeting properties in colorectal cancer models - after entering the hypoxic TME, the lipid shell disintegrated and released the nano-inducer. On the one hand, Fe3⁺ was converted to Fe2⁺ via the Fenton reaction, generating substantial amounts of toxic ROS; on the other hand, CGA and mitoxantrone synergistically inhibited the Xc−-glutathione peroxidase 4 (GPX4) pathway (a key regulatory axis of ferroptosis), facilitating the accumulation of lipid peroxidation and activating the antitumor immune response. This triple-modal therapeutic platform integrating hypoxia targeting, ferroptosis induction and immune stimulation drastically amplifies tumor cell damage, providing a novel strategy for precise treatment of colorectal cancer (Figure 6A). Schematic illustrations and in vivo antitumor evaluations of CGA-metal-based nanocomposites. (A) Schematic illustration of the construction of a hypoxia‑responsive nanoelicitor (HRNE) and the underlying mechanism that the activated tumoricidal immunity by HRNE attenuated GPX4 inhibition and synergistically potentiated lipid peroxidation and cancer cell ferroptosis.67 Copyright (2022) Elsevier. (B) Schematic illustration of CGA‑conjugated nanoparticles suppression of platelet activation and disruption to tumor vascular barriers for enhancing drug penetration in tumor. The synthetic procedure and proposed action mechanism of BDCCN in vivo.78 Copyright (2023) John Wiley and Sons Ltd. (C) Schematic illustration depicting the synthesis (i) and antitumor mechanism (ii) of ChA-Cu nanoparticles. (D) In vivo evaluation of antitumor activity. (i) Schematic of the experimental schedule for CT26 tumor-bearing mice. (ii) Tumor volume change during treatment. (iii) The individual tumor growth curves of mice after different treatments. (iv) Harvested CT26 tumor weight after different treatments. (v) Corresponding tumor photographs after 14 days of different treatments. (vi) Representative H&E, Ki67, and TUNEL immunohistochemical staining of tumor tissues after different treatments. Results were presented as mean ± SD (n = 5).66 Copyright (2025) Elsevier. (E) Schematic illustration depicting the synthesis and antitumor mechanism of AgNPs-CGA-BSA.77 Copyright (2022) American Chemical Society. (F) Schematic illustration of the synthesis pathway of CHSe NPs and its therapeutic mechanism in ALI.34 Copyright (2025) BioMed Central. (G) Synthesis route of TGN-CGA@SeNCs.93 Copyright (2023) American Chemical Society. Red cross marks indicate inhibition. Red arrows indicate the increase or decrease expression. **p < 0.01, ns: no significance. Scare bar: 50 μm or 100 μm. In addition, FeIII-doped two-dimensional nanomaterials (eg, FeIII-C3N4 nanosheets) possess a large specific surface area and pH/H2O2 responsive release properties, serving as a co-delivery carrier for CGA and chemotherapy drugs. Their unique advantage lies in the “anticoagulant effect” of combining with CGA, which solves the problem of “insufficient drug intratumoral perfusion” in tumor treatment. CGA prevent hypercoagulation by inhibiting platelet aggregation and down-regulating cyclooxygenase activity,94–98 while simultaneously reducing the secretion of tumor procoagulant factors (such as MMP-2, MMP-9, thrombin, and tissue factor TF), thereby inhibiting tumor-related hypercoagulation from the source.99–101 Ke et al78 developed the DCCN system (FeIII-C3N4 nanosheets co-loaded with CGA and doxorubicin), which fully utilized this property to achieve a triple synergistic effect: (1) FeIII provided coordination sites for CGA and doxorubicin, enhancing the drug loading efficiency, and responding to drug release in the acidic TME; (2) CGA inhibited tumor-related platelet activation, blocked the interaction between platelets and tumor endothelial cells, and disrupted endothelial junctions, enhancing the high permeability and retention effect, promoting the penetration of nanomedicines into tumor tissues; (3) CGA downregulated the expression of procoagulant factors, improving the tumor-related hypercoagulable state without systemic bleeding risk. This system effectively solved the problem of uneven distribution of chemotherapeutic drugs in tumor tissues, providing a “delivery-treatment-microenvironment regulation” integrated strategy for the treatment of solid tumors (Figure 6B). Copper-Bridged Nanoparticles Copper ions can trigger tumor cell ICD by inducing oxidative stress and cell pyroptosis, a process that releases DAMPs to activate the host’s specific immune responses. The coordination of CGA with Cu2⁺ can further enhance ICD effect while improving delivery targeting. CGA‑Cu nanoparticles (CGA‑Cu NPs) are formed through the self‑assembly of CGA and Cu2⁺ into a metal‑phenolic network structure (Figure 6C).66 Within the TME, these NPs can selectively release Cu2⁺ and CGA to exert synergistic therapeutic effects: on one hand, they disrupt intracellular redox homeostasis by generating ROS and depleting intracellular GSH, thereby inducing tumor cell apoptosis and increasing sensitivity to cuproptosis; on the other hand, combined cuproptosis and pyroptosis jointly provoke ICD, promote DAMPs release, stimulate dendritic cell maturation and CD8⁺ T‑cell activation, effectively reprogramming the tumor immune microenvironment. Animal experiments have confirmed that this system significantly inhibits tumor growth without causing notable systemic toxicity (Figure 6D). Beyond direct copper coordination, recent advances in cuproptosis-sensitizing strategies offer valuable insights for optimizing CGA-based nanoplatforms. For instance, Ning et al102 engineered a platelet vesicle-coated cuprous oxide system co-loaded with a type-I AIE photosensitizer (TBP-2). This design not only delivered copper ions but also utilized light-triggered photodynamic therapy to deplete intracellular glutathione and inhibit ATPase-mediated copper efflux, thereby potentiating cuproptotic efficacy. This synergistic approach, which combines ion delivery with metabolic modulation, provides a compelling rationale for further engineering CGA-copper systems to overcome resistance mechanisms inherent in the tumor microenvironment. Silver/Gold/Selenium-Based Nanocomposites Silver nanoparticles (AgNPs) emerged as promising carriers for CGA delivery, attributed to their excellent antioxidant, antibacterial and broad-spectrum anticancer activities. Moreover, the green synthesis process can enhance their biocompatibility.77,103–107 Roy et al77 further constructed AgNPs-CGA‑bovine serum albumin (AgNPs-CGA-BSA) complexes. In vitro experiments showed that this complex could efficiently scavenge 1,1-diphenyl-2-picryl-hydrazyl radical radicals and lipid peroxide radicals, and exhibited specific toxicity to Dalton’s lymphoma ascites (DLA) cells at a concentration of 2.5 μg/mL (IC50), while exerting no cytotoxicity toward normal mouse lymphocytes (MLC). In vivo experiments demonstrated that BSA could improve the host’s oxidative balance state by increasing the GSH levels and antioxidant enzyme activity in liver and kidney tissues, thereby indirectly enhancing the anticancer efficacy of CGA. This nanosystem provides a candidate low-toxicity therapeutic agent for oxidative stress-related tumors such as lymphoma (Figure 6E), with its core advantage lying in its “selective antitumor” via synergistically regulation between AgNPs and CGA, while preserving healthy somatic cells. Similarly, Hwang et al79 fabricated CGA‑gold nanoparticles (CGA-Au NPs), utilizing CGA as both a reducing agent and stabilizer: through the double-electron oxidation reaction of the caffeic acid structure in the CGA, Au3⁺ was reduced to Au0 with the concomitant formation of a quinone structure. This nanoparticle exerts synergistic anti-inflammatory and antitumor effects by inhibiting the NF-κB-mediated inflammatory pathway. Selenium is an essential trace element for the human body. Selenium nanoparticles (SeNPs) have been extensively applied in anti-inflammatory, antioxidant and drug delivery fields, attributed to their low toxicity, good biocompatibility and strong redox activity.108 The combination of CGA and SeNPs can alleviate the adverse effects of tumor treatment via “anti-inflammatory‑antioxidant synergy”, and achieve precise delivery to specific tissues (eg, the brain) through targeted modification strategies. Xing et al34 developed synergistic selenium-based CGA nanoparticles (CHSe NPs), which form a stable structure by coating the surface of SeNPs with the conjugate of CGA and human serum albumin. In acute lung injury mouse model, CHSe NPs exhibited superior efficacy to the clinical agent dexamethasone: synergistic SeNP-CGA activity reduces pulmonary ROS levels and elevates SOD and glutathione peroxidase activity; simultaneously, the nanosystem reverses M1 macrophage polarization (promoting M2 phenotypic conversion), downregulates expression of proinflammatory mediators (IL-1β, TNF-α, iNOS, myeloperoxidase) and upregulates anti-inflammatory IL-10 secretion, effectively reducing neutrophil infiltration and inflammatory tissue damage (Figure 6F). This nanosystem provides a valuable reference for mitigating inflammation-associated adverse effects induced by tumor therapies (eg, radiotherapy and chemotherapy). Although CGA has neuroprotective effects, its low bioavailability, necessitating high doses, and poor blood–brain barrier (BBB) penetrability limit its application for central nervous system disorders including Alzheimer’s disease (AD) and brain tumors. Building on Li et al’s earlier finding that selenium nanoparticles can enhance the biological activity of resveratrol,109 researchers further designed TGN-CGA@SeNC—brain-targeting peptide-modified flower-shaped selenium nanoclusters.93 Specifically, CGA was conjugated to the BBB-targeting peptide TGN (sequence: TGNYKALHPHNG) on the surface of selenium nanoclusters, markedly improving CGA’s solubility, stability, and BBB penetration efficiency (Figure 6G). In APP/PS1 transgenic mice (an AD model), at the same dose, TGN-CGA@SeNC exhibited superior efficacy in enhancing the cognitive function of mice compared to free CGA or non-targeted CGA@SeNC. It also showed more pronounced effects in alleviating Aβ peptide aggregation, neuroinflammation, oxidative stress, and gut microbiota dysbiosis. This nanosystem significantly reduced CGA’s effective therapeutic dose, offering a novel strategy for the efficient translation of CGA in brain disorders (including brain tumors). CGA-metal nanoparticle composite systems effectively overcome the limitations of CGA—including short in vivo circulation time and low tumor accumulation—through two complementary mechanisms: enhanced pharmacokinetics via carrier-mediated delivery and potentiated antitumor efficacy through functional synergy. These nanosystems directly eliminate tumor cells via mechanisms such as ferroptosis, cuproptosis, and oxidative stress modulation, while indirectly improve therapeutic outcomes by activating antitumor immune responses and ameliorating the TME (ie, via anticoagulant and anti-inflammatory effects). Additionally, surface functionalization enables tissue-specific targeted delivery. Collectively, these studies offer diversified nanocarrier platforms for the clinical translation of CGA. However, future research should focus on in-depth investigation of long-term biosafety, scalable manufacturing processes, and clinical efficacy validation to facilitate its translation from basic research to clinical practice. Metal Oxide Nanocarriers Metal oxide nanomaterials have emerged as a prominent type of targeted delivery vehicles for CGA, owing to their tunable morphology, superior chemical stability, unique physicochemical properties (eg, magnetic responsiveness and photocatalytic activity), and favorable biocompatibility. Their core advantage resides in mitigating the limitations of poor stability and inadequate targeting in CGA delivery via surface or functional modification, while augmenting antitumor efficacy by exerting functional synergy with CGA through their intrinsic properties (eg, magnetism and oxidative activity). Tin Oxide Nanoparticles for Apoptosis Tumor Ablation Tin oxide (SnO2) nanoparticles, as n-type semiconductor materials, exhibit potent oxidative activity, tunable morphological features, low cytotoxicity, and excellent photodegradation resistance,110,111 rendering them a promising platform for the stable loading of CGA and tumor ablation. Shakila et al62 designed and synthesized a composite hollow SnO2-sodium alginate-CGA nanocomposites (SnO2-SA-CGA HNM) to enhance the anticancer efficacy against triple-negative breast cancer (TNBC) MDA-MB-231 cells. This nanomaterial enables the stable conjugation of CGA and SnO2 via a biocompatible sodium alginate scaffold. Upon internalization into tumor cells, two key mechanisms underpin its therapeutic effect: first, the oxidative activity of SnO2 synergizes with CGA to markedly elevate intracellular oxidative stress levels; second, it modulates apoptosis-related signaling pathways (eg, activating Caspase family proteins) to induce MDA-MB-231 cell apoptosis. In vitro studies verified that SnO2-SA-CGA HNM exerts potent proliferation-inhibitory activity against MDA-MB-231 cells, with lower cytotoxicity than free CGA or pristine SnO2 nanoparticles—highlighting its great potential as a candidate therapeutic agent for TNBC (Figure 7A). Schematic illustrations and in vivo antitumor evaluations of CGA-metal oxide nanocarriers. (A) Effect of SnO2 -SA-CA HNMs on the apoptotic cell death (i) and the oxidative stress biomarkers MDA, GSH, CAT and SOD (ii) in the MDA-MB-231 cells.62 Copyright (2025) Association of Pharmaceutical Teachers of India. (B) Schematic representation of the possible mechanism of 5-CQA-Fe3O4 NPs@OVA-induced apoptosis on MDA-MB-231 cells. (C) Cell cycle analysis of MDA-MB-231 cells and Fluorescence microscopic images of intracellular ROS and (D) production after treatment with control (untreated cells) (i), C-Fe3O4 NPs (ii), 5-CQA (iii), C-Fe3O4 NPs@OVA (iv), 5-CQA–C-Fe3O4 NPs (v), and 5-CQA–C-Fe3O4 NPs@OVA (vi) at 24 h.80 Copyright (2022) Royal Society of Chemistry. *p < 0.05. Scale bar: 100 μm. Magnetic Responsive Delivery of Iron Oxide Nanoparticles Iron oxide (Fe3O4) nanoparticles have been extensively utilized in cancer theranostics (integrated diagnosis and treatment) owing to their magnetic responsiveness (enabling in vitro separation and in vivo targeted localization), favorable biocompatibility, and capacity to elicit therapeutic effects.112 However, pristine Fe3O4 nanoparticles suffer from two key limitations: strong interparticle magnetic dipole interactions induce severe aggregation, compromising aqueous dispersibility; limited surface functional groups restrict drug loading capacity and targeted surface modification.113 To overcome these challenges, Manive et al80 functionalized Fe3O4 nanoparticles with ovomucin (OVA) to construct C-Fe3O4 NPs@OVA composite carriers for loading 5-camptothecic acid (5-CQA), a CGA analog with analogous antitumor activity (Figure 7B). This carrier exhibits three core advantages: (1) The hydrophilic moieties of OVA improve the dispersibility of Fe3O4 nanoparticles while providing abundant binding sites, thereby enhancing the loading efficiency and stability of 5-CQA; (2) In vitro drug release assays demonstrate that C-Fe3O4 NPs@OVA enables sustained, controlled release of 5-CQA, circumventing the burst release effect associated with free 5-CQA; (3) In vitro assays using MDA-MB-231 triple-negative breast cancer cells confirm that 5-CQA-loaded C-Fe3O4 NPs@OVA exerts significant dose-dependent cytotoxicity. Further, flow cytometry and intracellular oxidative stress analyses verify that this carrier augments the antitumor efficacy of 5-CQA by elevating intracellular ROS levels and activating apoptotic signaling pathways (Figure 7C and 7D), with tumor growth inhibitory effect markedly superior to free 5-CQA. Additionally, the magnetic responsiveness of Fe3O4 enables in vivo targeted localization of the system, laying a robust foundation for subsequent theranostic research. Functionalized Liposomes for Immunomodulation Beyond metal oxide nanoparticles, surface-functionalized liposomal carriers exhibit unique advantages for CGA-targeted delivery, particularly with respect to TME immune microenvironment regulation. Ye et al10 developed a mannosylated CGA liposome delivery system targeting TAMs in glioblastoma (Figure 8A). To address the low lipophilicity of CGA and its difficulty in integrating into the liposome membrane, a CGA-phytosphingosine complex was prepared as an intermediate,114 significantly enhancing the lipophilicity of CGA and promoting its hydrophobic interaction with the liposome. Mannosylated molecules were further modified on the liposome surface to achieve targeted binding through the high expression of mannosyl receptor on the surface of TAMs. This system demonstrated efficient targeting in the G422 glioma model: The mannosyl-mediated active targeting enabled CGA to precisely accumulate in TAMs, promoting the polarization of TAMs from the pro-tumor M2 type to the antitumor M1 type, reshaping the tumor immune microenvironment, and simultaneously inhibiting the proliferation of glioma cells. Animal experiments showed that this delivery system could significantly inhibit the growth of G422 tumors, without causing obvious neurotoxicity, providing a new approach for immunotargeted therapy of GBM (Figure 8B). Schematic illustrations and in vivo antitumor evaluations of CGA-based immunomodulation and combinatorial therapeutic strategies. (A) Schematic overview of CHA-encapsulated Man-PEG-Lipo that enhances tumor accumulation via active targeting to mannose receptor-expressing TAMs and promotes the polarization of TAMs for cancer immunotherapy. (B) (i) The schematic of treatment schedule. The images of excised tumors (ii), tumor volume changes (iii), tumor weight (iv), and body weight changes (v) of murine G422 glioma tumor-bearing mice after interval intravenous treatment of CHA-encapsulated liposomes. Each value represents the mean ± SEM (n = 6).10 Copyright (2020) KeAi Communications Co., Ltd. ** p < 0.01, *** p < 0.001. Arrows represent activation; T-bars represent inhibition. Combinatorial Therapeutic Strategies: CGA Combined with Chemotherapy/Immunotherapy CGA’s immunomodulatory activity (TAM polarization regulation, T cell effector function enhancement) synergizes with chemotherapy or immune checkpoint inhibitors to achieve “1+1 > 2” antitumor effects, addressing clinical challenges such as drug resistance and low immunotherapy response rates. CGA-Chemotherapy Combinatorial Therapy The combination of CGA and chemotherapy drugs achieves synergistic efficacy by dual-pathway inhibition. For example, regorafenib (a multi-kinase inhibitor) inhibits the MAPK pathway but has limited effect on the PI3K/Akt/mTOR pathway.37 CGA synergizes with regorafenib to inhibit PI3K/Akt phosphorylation and downregulate mTOR expression, significantly suppressing hepatocellular carcinoma cell proliferation and inducing apoptosis. Similarly, CGA-doxorubicin co-delivery via FeIII-C3N4 nanosheets enhances intratumoral drug distribution and synergistic cell killing. CGA inhibits P-glycoprotein expression in tumor cells, reversing doxorubicin resistance, while doxorubicin enhances CGA-induced DNA damage by inhibiting topoisomerase II (Figure 6B).78 CGA-Immunotherapy Combinatorial Therapy Li et al26 tackled the challenge of immunotherapy resistance in melanoma by developing a combinatorial therapeutic regimen comprising sialic acid-modified CGA liposomes (CGA-SAL) and anti-PD-1 antibodies (Figure 9A). This study was conducted in a B16 F10 melanoma mouse model, where mice were randomized into four groups: untreated control, anti-PD-1 antibody monotherapy, CGA-SAL monotherapy, and CGA-SAL + anti-PD-1 antibody combination therapy (Figure 9B). Results demonstrated that the combination group displayed robust synergistic antitumor activity compared with the monotherapy and control groups: the proportions of pro-tumor M2-type TAMs and immune-suppressive CD4⁺Foxp3⁺ Tregs in the TME were markedly decreased, whereas the proportions of antitumor M1-type TAMs and CD8⁺ cytotoxic T cells, along with T cell effector function (eg, IFN-γ secretion levels), were significantly enhanced (Figure 9B–D). Meanwhile, pathological examination of major organs (heart, liver, spleen, lung, and kidney) detected no overt toxicity, validating the safety profile of the combinatorial regimen. This dual-modal therapeutic platform operates via two complementary core mechanisms: first, CGA-SAL facilitates the targeted accumulation of CGA in tumor tissues via sialic acid-mediated delivery, which modulates the tumor immune microenvironment to reverse immune suppression; second, anti-PD-1 antibodies block the PD-1/PD-L1 axis and potentiate the cytotoxic function of CD8⁺ T cells. These complementary actions synergistically boost the response rate to immune checkpoint inhibition. Collectively, these findings demonstrate that CGA-SAL combined with anti-PD-1 antibodies holds substantial promise for melanoma treatment and provides a novel combinatorial strategy to improve clinical immunotherapeutic efficacy. Beyond tumor-targeted delivery and checkpoint blockade, a more ambitious biomimetic strategy involves engineering the nanocarrier itself as an immunostimulatory agent. In a groundbreaking study, Suo et al115 constructed an organic nanozyme (DMIC) camouflaged with mature dendritic cell membranes. This biomimetic system functions as an artificial antigen-presenting cell, capable of directly homing to tumor-draining lymph nodes and spleens, activating CD8⁺ T cells, and simultaneously releasing an ammonia metabolism modulator (CB-839) to counteract ammonia-induced T lymphocyte death—a previously unrecognized mechanism of T cell exhaustion. This design, which integrates near-infrared photodynamic therapy, peroxidase-like catalytic activity, and metabolic modulation within a single biomimetic platform, represents a paradigm shift from passive drug delivery to active immune reprogramming. Such a “tumor vaccine” concept could be adapted to CGA-based systems, potentially broadening their therapeutic impact beyond the direct modulation of TAMs and Tregs, and positioning CGA as a central player in next-generation cancer immuno-nanomedicine. Schematic design and in vivo and in vitro experimental verification of CGA-based combined immunotherapy against tumors. (A) Schematic illustration depicting the synthesis and antitumor mechanism of CA-SAL and anti-PD1. (B) (i) Illustration of the design of the experiments. (ii) Tumor volume change curve of tumor-bearing mice (vs control group). (iii) Tumor inhibitions rate of tumor-bearing mice. (iv) Body weight curve of tumor-bearing mice. (v) Survival rate of the tumor-bearing mice receiving different treatment. The values are shown as mean ± SEM (n=4-6). (C) The in vivo polarizability of TAMs in the administration group was assessed by analyzing the proportion of M1/M2 subtype macrophages in the tumor tissue. (i) The proportion of M1-TAMs (CD45+F4/80+CD11b+CD86+) (vs anti-PD1+ CA-SAL). (ii) The proportion of M2-TAMs (CD45+F4/80+CD11b+CD206+) (vs control group). (iii) The ratio of M1/M2 TAMs (vs control group). The values are shown as mean ± SEM (n=4-6). (D) The activity of T cells in the administration group was assessed by analyzing the proportion of CD4+ and CD8+ T cells in the tumor tissue. (i) The proportion of CD4+ T cells. (ii) The proportion of CD4+ Foxp3+ T cells (vs control group). (iii) The proportion of CD8+ T cells (vs anti-PD1+ CA-SAL). The values are shown as mean ± SEM (n= 4–6).26 Copyright (2021) Informa Healthcare. (E) Flow cytometry analysis of (i) M1 macrophage (CD86+) polarization and (ii) M2 macrophage (CD206+) polarization levels in different experimental groups. All experiments were repeated three times.116 Copyright (2025) Wiley. (F) (i) MDA-MB231 cells were pre-treated with each compound for 24 h and then co-cultured with Jurkat cells. After 24 h, Jurkat cells were removed, and the remaining MDA-MB231 cells were quantified. (ii) Following co-culture, the NFAT activity of Jurkat cells was measured. (iii) The levels of IFN-γ-inducible PD-L1 protein in DLD-1 cells were analyzed via Western blotting bergenin (BG), catechin (CT), chlorogenic acid (CA), ellagic acid (EA), and gallocatechin (GC)117 Copyright (2024) MDPI. (G) (i) Statistical analysis of tumour weights in the aforementioned groups (n = 5). (ii) Statistical analysis of SIRPA results for F4/80+ cells in MC38 tumour tissues from mice treated with STM2457 (50 mg kg −1, i.p) and CHA (50 mg kg −1, i.p) and the model group (n = 5).118 Copyright (2026) Elsevier. Red arrows indicate the increase or decrease expression. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 and ns: no significance. Beyond melanoma, recent studies have extended the therapeutic strategy of CGA combined with immune checkpoint inhibitors to various solid tumor models. Rao et al116 revealed a novel immunometabolic regulatory pathway in a urethane-induced lung adenocarcinoma mouse model: CGA significantly reduces the serum level of the pro-tumor secondary bile acid taurodeoxycholic acid (TDCA), thereby blocking the TDCA-activated TGR5/STAT3 signaling axis and driving TAMs to repolarize from the immunosuppressive M2 phenotype toward the antitumor M1 phenotype. Specifically, this study found that high-dose CGA (200 mg/kg) treatment increased the proportion of M1 macrophages (CD86⁺) by approximately 4.1-fold, while reducing M2 macrophages (CD206⁺) by about 51%, accompanied by upregulation of TNF-α and downregulation of TGF-β. Mechanistically, TDCA, as an endogenous ligand of TGR5, induces STAT3 phosphorylation at Tyr705 to promote M2 polarization; CGA intervention effectively reverses this process. Furthermore, in an in vitro PBMC-tumor cell co-culture system, the TGR5 inhibitor SBI-115 completely blocked TDCA-induced p-STAT3 upregulation, confirming the specificity of this signaling axis (Figure 9E). Notably, although cisplatin exerts direct cytotoxic effects on tumor cells, it paradoxically promotes M2 macrophage polarization, which may compromise its long-term immunotherapeutic efficacy; in contrast, the unique immunomodulatory capacity of CGA establishes its theoretical foundation as an immunotherapy sensitizer. Two independent complementary regulatory axes mediate CGA’s synergistic anti-tumor immunity against colorectal cancer. First, Kim et al117 screened the active components of Caryophylli Cortex and identified CGA as a potent inhibitor of IFN-γ-inducible PD-L1 expression in cancer cells via the p-STAT1-IRF1 pathway. In a humanized PD-1/PD-L1 knock-in MC-38 colon cancer mouse model, oral administration of CGA-enriched extract achieved a tumor suppression rate of 73.03%, accompanied by increased intratumoral CD8⁺ T cell infiltration and granzyme B levels, without observable toxicity. Mechanistically, CGA directly suppresses PD-L1 expression on tumor cells, whereas other components such as ellagic acid block PD-1/PD-L1 protein interaction, collectively enhancing T cell activity (Figure 9F). Then, Zhou et al118 identified CGA as a novel inhibitor of methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit (METTL3), the catalytic core of the m6A methyltransferase complex. Mechanistically, METTL3 enhances SIRPA mRNA stability via an m6A-IGF2BP2-dependent mechanism, increasing surface expression of SIRPA on macrophages and suppressing phagocytosis. CGA inhibited METTL3 enzymatic activity (IC50 = 4.701 μM) and reduced its protein expression, thereby downregulating SIRPA and restoring macrophage phagocytic capacity against colorectal cancer cells. In an MC38 syngeneic mouse model, CGA (50 mg/kg, i.p) significantly suppressed tumor growth and reduced SIRPA expression on intratumoral F4/80⁺ macrophages (Figure 9G). In summary, the sialic acid-targeted CGA liposome plus anti-PD-1 regimen delivers robust therapeutic efficacy against melanoma. More importantly, multi-tumor preclinical data spanning lung adenocarcinoma and colorectal cancer have deciphered diverse complementary mechanisms of CGA as an immunotherapeutic adjuvant: metabolic reprogramming of bile acid signaling, TAM phenotype switching, epigenetic regulation of macrophage phagocytosis, and direct inhibition of tumor PD-L1 expression. Collectively, these consistent preclinical outcomes across multiple solid malignancies demonstrate that CGA serves as a versatile multi-target immunomodulator capable of sensitizing immune checkpoint inhibitors, establishing a broadly applicable combinatorial therapeutic paradigm to improve clinical response rates for diverse solid tumors. Discussion As a natural polyphenolic compound, CGA holds considerable promise for tumor therapy owing to its multi-targeted and multi-pathway antitumor mechanisms, and excellent biological safety profile. This review systematically elaborates the molecular mechanisms underlying CGA’s antitumor effects and the research progress of its clinical translation facilitated by nanocarriers. Core findings highlight CGA’s unique advantages as a natural candidate antitumor agent and offer multi-faceted strategies to advance its clinical application. Firstly, CGA’s antitumor effects feature prominent multi-targeted synergism, exerting actions at multiple levels: encompassing tumor cell proliferation inhibition, inflammatory microenvironment modulation, and immune response activation, all achieved via the regulation of three core signaling pathways (JAK-STAT, NF-κB, and MAPK). On one hand, CGA targets key molecules (eg, STAT1/STAT6, IKK/IκBα, ERK/JNK) to directly suppress the malignant phenotype of tumor cells; on the other hand, it drives the polarization of TAMs from the pro-tumor M2 subtype to the antitumor M1 subtype, enhances the functions of CD8⁺ T cells and NK cells, and modulates the balance of immune factor networks. This comprehensive remodeling of the tumor immune microenvironment TIME overcomes the inherent limitation of traditional chemotherapeutics—“prioritizing killing while neglecting immunity”.21,41 Notably, CGA metabolites (eg, caffeic acid, 3-PPA) also exhibit apoptosis-inducing activity, forming a “parent compound-metabolite” synergistic antitumor network.48 This unique trait further reinforces the durability and efficacy of CGA’s antitumor actions. Secondly, nanocarrier technology serves as a pivotal strategy to overcome the pharmacokinetic bottlenecks of CGA. This review encompasses diverse nanosystems, including metal ion composite systems (eg, iron-based composites, copper-coordinated nanoparticles, silver nanoparticles), metal oxide nanomaterials (SnO2, Fe3O4), and functionalized liposomes. These nanoplatforms enable efficient CGA delivery via distinct mechanisms: Iron-based ferroptosis-targeted systems utilize hypoxia-responsive release to realize triple synergy of “targeted delivery - ferroptosis induction - immune activation;73 copper-coordinated nanoparticles induce ICD reprogramming of the tumor immune microenvironment while mitigating systemic toxicity;72 brain-targeting peptide-modified selenium nanoclusters significantly improve CGA’s BBB penetration efficiency, offering novel insights for the treatment of brain tumors and neurological disorders.96 Compared with conventional carriers, these nanosystems not only enhance CGA’s solubility, stability, and tumor tissue accumulation efficiency, but also achieve the integration of “delivery - therapy - microenvironment modulation” via the synergistic amplification of “carrier functionality - CGA activity”—exhibiting substantial superiority over free CGA or monotherapeutic approaches.91 Furthermore, combinatorial therapeutic strategies pairing CGA with chemotherapeutic agents (eg, regorafenib, doxorubicin) or immune checkpoint inhibitors (eg, anti-PD-1 antibodies) exert a potent “1+1 > 2” synergistic antitumor effect. For instance, the combination of CGA and regorafenib enables dual inhibition of the MAPK and PI3K/Akt/mTORC signaling pathways,38 while CGA combined with anti-PD-1 antibodies enhances immunotherapeutic response rates by modulating TAM polarization and T cell subset homeostasis.21 This offers a promising avenue to address critical challenges in clinical oncology, such as tumor drug resistance and suboptimal immunotherapeutic response rates. Nevertheless, a more balanced appraisal requires attention to several underdiscussed limitations. Several low-dose in vivo studies reported trivial tumor-suppressive effects of free CGA due to rapid metabolic clearance, and certain metal nanoparticle-CGA formulations failed to achieve expected ferroptosis/immunogenic cell death efficacy under normoxic tumor microenvironments, which are rarely elaborated in existing reviews. Moreover, clinical evidence gaps remain prominent: no large-scale Phase II/III clinical trials have validated the standalone or combined antitumor efficacy of CGA, while multiple alternative natural polyphenols (curcumin, epigallocatechin gallate) with analogous multi-target anti-tumor activity have been more extensively advanced in clinical translational research. Expanded discussion of these conflicting findings, failed formulation strategies and competing therapeutic candidates will help construct a more objective and balanced evaluation system for CGA as a natural anticancer agent. Despite these encouraging preclinical advances, multiple unresolved translational hurdles persist, creating a stark disconnect between robust preclinical efficacy and limited clinical evidence. First, the long-term biosafety of nanocarriers for CGA delivery remains incompletely elucidated. Certain metal-based nanoparticles carry a potential risk of systemic accumulation, which warrants rigorous and systematic toxicological investigations.72,91 Second, most existing studies are confined to in vitro cellular and in vivo animal models, resulting in limited clinical evidence. To date, no CGA-based nanomedicine has entered clinical trials for antitumor therapy, highlighting a critical evidence gap that must be addressed. Third, the large-scale standardized preparation of CGA nanocarriers remains a significant hurdle. Batch-to-batch consistency, storage stability, and sterilization processes pose substantial challenges for good manufacturing practice compliance, which are rarely discussed in current literature. Fourth, the individual variability in treatment response is often overlooked. The expression levels of key targets (eg, p53 mutation status, STAT3 activation levels) vary widely among patients, and CGA’s multi-target nature may lead to unpredictable efficacy across different tumor types and individual genetic backgrounds.27,54 Additionally, several key questions surrounding CGA’s mechanisms of action remain unclear—including the crosstalk networks among distinct signaling pathways regulated by CGA, as well as its effects on non-immune stromal cells (eg, tumor-associated fibroblasts) within the TME—all of which demand further in-depth investigation. Future research may focus on the following directions: (1) Fabrication of intelligent responsive nanocarriers: develop pH/ROS dual-responsive, multi-receptor targeted multifunctional nanoplatforms, with emphasis on orally bioavailable formulations to overcome the gastrointestinal metabolic degradation of CGA. Emerging stimuli-responsive platforms enable sustained and amplified therapeutic effects, as exemplified by the X-ray-triggered cascade nanoplatform, which achieves sustained ROS generation and immunogenic cell death through GSH-responsive release,119 offering a blueprint for spatiotemporally controllable CGA nanocarriers. Furthermore, to address the physical barrier and mechanotransduction-mediated survival signals arising from pathological ECM remodeling in solid tumors, ECM-modulating modules, targeting matrix stiffening, mechanotransduction blockade, and fibro-inflammatory suppression,120 can be integrated with pH/ROS-responsive CGA carriers to achieve a triple-action synergy of “drug release–matrix penetration–signal blockade”, thereby coupling time-amplification with space-penetration strategies into a synergistic therapeutic loop. (2) Optimize combinatorial therapeutic regimens: explore the novel synergistic mechanisms of CGA in combination with radiotherapy, CAR-T cell therapy, and other modalities, conduct stratified preclinical efficacy verification based on different tumor subtypes to broaden applicable patient populations. Furthermore, the combination of CGA-based cuproptosis induction with other therapeutic modalities, such as type-I photodynamic therapy as demonstrated in platelet-mimetic systems,102 could be explored to achieve multi-mechanistic tumor ablation and potentiate immune responses beyond current ferroptosis-based strategies. (3) Advance personalized treatment research: establish stratified tailored CGA dosing regimens based on patient tumor molecular profiling (p53 mutation status, signaling pathway activation levels) and individual intestinal metabolic phenotypes, mitigating interindividual variability in therapeutic response. (4) Refine the large-scale fabrication processes of nanocarriers: reduce production costs, and intensify long-term biosafety evaluations covering liver, kidney and nervous system accumulation risks, thereby laying a solid foundation for CGA’s clinical translation. Conclusion CGA is a natural bioactive compound with potent antitumor effects, mediated by multi-pathway regulation (JAK-STAT, MAPK, NF-κB), antitumor immune enhancement, and tumor cell apoptosis induction. Despite its inherent limitations (low bioavailability, poor tumor targeting), nanocarrier technology (metal-based nanocomposites, metal oxides, functionalized liposomes) has significantly improved CGA’s delivery efficiency and therapeutic specificity. Moreover, CGA-based combinatorial therapy exhibits robust synergistic effects with chemotherapy and immunotherapy, providing a novel strategy for holistic tumor treatment. However, the path to clinical translation is fraught with practical obstacles, including the absence of clinical trial data, unresolved long-term biosafety of nanocarriers, challenges in scalable good manufacturing practice-compliant manufacturing, and patient-specific variability in treatment response. To accelerate CGA’s clinical translation, future efforts should focus on optimizing nanocarrier formulation, conducting rigorous safety assessments, and developing personalized therapeutic strategies. With multidisciplinary collaboration, CGA holds great promise to evolve from a preclinical candidate to a clinical precision antitumor agent. Funding Statement This work was supported by Key Project of Health Science and Technology Program of Inner Mongolia Autonomous Region of China (2025WSJK002) and Natural Science Foundation of Inner Mongolia Autonomous Region of China (2025QN08122). Abbreviations CGA, Chlorogenic acid; JAK-STAT, Janus kinase-signal transducer and activator of transcription; MAPK, Mitogen-Activated Protein Kinase; NF-κB, Nuclear factor kappa-B; Bcl-2, B-cell lymphoma 2; TME, Tumor microenvironment; TAMs, Tumor-associated macrophages; STAT, Signal transducer and activator of transcription; LPS, Lipopolysaccharide; IFN-γ, Interferon-gamma; Tregs, Regulatory T cells; ERK, Extracellular signal-regulated kinase; JNK, Jun N-terminal kinase; COX-2, Cyclooxygenase-2; PI3K, Phosphatidylinositol 3-kinase; AKT, Protein kinase B; mTOR, mammalian target of Rapamycin; IκB, inhibitor of NF-κB; IκBα, Inhibitor of the nuclear factor kappa B; IKK, the IκB kinase; TNF-α, Tumor necrosis factor-α; IL, Interleukin; TLR, Toll-like receptor; ROS, reactive oxygen species; AMPK, 5′-adenosine-monophosphate-activated protein kinase; SIRT1, Silent information regulator 1; SOD, Superoxide dismutase; PI3K, Phosphatidylinositol 3-kinase; AKT, Protein kinase B; JAK, Janus kinase; SOCS3, Suppressor of cytokine signaling 3; NK cells, natural killer cells; MCP-1, Monocyte chemoattractant protein‑1; MIP-1α, Macrophage inflammatory protein‑1α; GSH-Px, glutathione peroxidase; CAT, catalase; GSH, sufficient reduced glutathione; Nrf2, Nuclear factor erythroid-2-related factor 2; HO-1, Heme oxygenase-1; MDA, malondialdehyde; Bax, Bcl-2-associated X; 3-PPA, 3-phenylpropionic acid; mtDNA, mitochondrial DNA; nucDNA, nuclear DNA; MMP, Matrix metalloproteinase; PKC, protein kinase C; ICD, Immunogenic death; DAMPs, Damage-associated molecular patterns; GPX4, glutathione peroxidase 4; MLC, mouse lymphocytes; BBB, Blood–brain barrier; AD, Alzheimer’s disease; OVA, Ovomucin; TDCA, Taurodeoxycholic acid; METTL3, Methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit; anti-PD-1, Anti-programmed cell death protein 1; DLA, Dalton’s lymphoma ascites. Disclosure The author(s) report no conflicts of interest in this work. References